Langzeitbehandlung der renalen Anämie mit Mesterolon

Publisher Website
Google Scholar
Abstract
Mesterolone, 150 mg daily by mouth, was given to 26 patients (10 men, 16 women) with renal anemia on chronic hemodialysis (3 times for 5 h). At the beginning of treatment the patients were dialysed for at least 6 mo. under stable conditions: Fe deficiency was excluded or treated. Progressive improvement in the anemia was observed during the treatment period. After 39 mo. the Hb concentration had risen from 74 .+-. 4 g/l to 95 .+-. 5 g/l, hematocrit from 0.22 .+-. 0.01 to 0.28 .+-. 0.02, and the red-cell count from 2.44 .+-. 0.12 .times. 1012/l to 3.09 .+-. 0.2 .times. 1012/l. Side effects were rare; some patients developed increased appetite with a rise in body weight, while some women developed acne or hirsutism. There was no effect of mesterolone on liver function. Mesterolone can favorably influence renal anemia and the side effects of this testosterone derivative are not such as to prohibit its use in women.

This publication has 1 reference indexed in Scilit: